Neuren Pharmaceuticals Limited

ASX (AUD): Neuren Pharmaceuticals Limited (NEU)

Last Price

13.29

Today's Change

-0.38 (2.77%)

Day's Change

13.24 - 13.94

Trading Volume

320,043

Overview

Market Cap

1 Billion

Shares Outstanding

127 Million

Avg Volume

608,465

Avg Price (50 Days)

12.87

Avg Price (200 Days)

15.99

PE Ratio

13.98

EPS

0.95

Earnings Announcement

04-Mar-2025

Previous Close

13.67

Open

13.90

Day's Range

13.24 - 13.94

Year Range

10.9 - 24.0

Trading Volume

320,090

Price Change Highlight

1 Day Change

-2.85%

5 Day Change

-9.10%

1 Month Change

8.85%

3 Month Change

8.41%

6 Month Change

-28.79%

Ytd Change

8.41%

1 Year Change

-41.13%

3 Year Change

240.51%

5 Year Change

386.45%

10 Year Change

302.42%

Max Change

132.57%

News and Blogs
Latest Hottest Following

No result.

Company Profile

Sector: Healthcare - Healthcare

Industry: Biotechnology

Description:

Neuren Pharmaceuticals Limited, a biopharmaceutical company, develops drugs for the treatment of neurological disorders. Its lead product is trofinetide, which is in Phase III clinical trial for the treatment of Rett syndrome, as well as has completed Phase II clinical trial to treat Fragile X syndrome. The company also develops NNZ-2591, which has completed Phase I clinical trial for the treatment of Phelan-McDermid, Angelman, Pitt Hopkins, and Prader-Will syndromes. In addition, it provides development services; and holds loan funded shares. The company was incorporated in 2001 and is based in Camberwell, Australia.

Discussions
Be the first to like this. Showing 0 of 0 comments
Post a Comment